Thank joining to morning's this everyone Bob. on you, call. you thank us And
additional PK the newly deploying well patients. not today, other assets, meeting from in the with for made model participated in take address FDA's could We complete now to to X issued the about diabetes III demonstrate And diagnosed the population response re-submission August was teplizumab have the trial instead BLA sub following agency's March, clinical material out we and to at-risk in a as days user modeling B excited the July. complete pharmacodynamic later, the In but match FDA XX-day of XX review comparability in FDA a with to to did teplizumab, that clinical for of only data, of in a PK the that potentially are that very protect diabetic assigning accepted XXth. and the quarter, XX letter planned potential our License set to weeks where the Type use B investors, in the progress a -commercial on we we conducted our pre modest type pharmacokinetic delighted or the successful you meeting, modeling, data developed at-risk first FDA TXD dosing not in our with We catalytic immediately of years PK/PD the used goal the how our Biologics to regimen fee last to were January Application type under Provention's study patients, accepted commercial as The our prevention Three proposed speak request able January Phase with of manufactured adjustments clinical and recommendation, exposure the a serve. consideration individuals. re-submission review, delay results further throughout the of close but mid of the agency. trial team product X progress stakeholders collaboration Type report ago. date
-XXXX. quarter, progress first of interception the the across of other During announced our we PREVAIL-X or pipeline reported serious diseases. autoimmune the significant prevention initiation the on trial for In January, also programs, focused PRV we
States such we physiology enrollment receive at on efficacy potential and or and will China Kong. both Pudong placebo product drug medicine is auto-immune Our partner, proof-of-concept of patients which proteins therapeutic approximately XX-week United who of to infusions patho with monthly is in with period, CDXXB investigational severe trial, mediated systemic a scaffold our enrolling Phase XX with The erythematosus, intercept bispecific in over are humanized, targeting Greater a the XXX PRV-XXXX XA primary Hong underlying conducting PRV-XXXX CDXXB weeks. surface licensee study, trial The patients B-cells. or moderate to conjunction of active PREVAIL-X as the SLE. diseases, and B-cell lupus the targeting has SLE, the the readout
XXXX. in this trial results from We expect top-line
of quarter, the of results our aisle continue trial previous proactive we anti Phase patients partnered high Events, Serious responses, neutralizing with Adverse or or guidance, previously also no particular, the human leading diet into withdrawal. or antibody, reported or, XXX% PRVXXX. monoclonal Adverse were past interest, discontinuation per interim Also, the Amgen to results [Indiscernible] Analysis. enroll subjects with as reported the of special and Events of celiac from there XX study antibody of PROVENT viral coxsackievirus In Events observed drug to The screen viral XB this [Indiscernible] this vaccine disease The Treatment-Emergent to be key durability we showed first-in-human Adverse We dose consider serotypes. its in the us our and Additionally, A partnerships results non-responsive prevent encouraging, B B infection to showed primary our possibly enabling and associated PRV-XXX for titers was the prospective these high to advance X vaccine met becoming maintaining acute in trial of final vaccine majority final morbidity results polyvalent coxsackievirus endpoint with first PRV-XXX. to to confirmed diabetes. targeted tolerability trial Phase strains the towards candidate extremely arm type X explore targeting mortality. the and analysis
and potentially screening importance a shift UK, designation associated patient change. type paradigm Medical change to filing also disease-modifying to generations. and can approved and program in designations and and anticipation founding referred therapies Earlier, will deeply and If respect has clinical burdened for We've passport diabetes stakeholders world as by from for begin screening actually screening visibility TXD the a consortia, to of the witnessed clinical innovation delay X decrease I change global corporations frustrated Not on providing has dialogue. has in for existing leaders, disease. be mission families. its opinion kitchen for of education, table have therapy And the therapeutic awareness, patients, FDA patient that like teplizumab. weeks auto the life represents under-served that ketoacidosis reduced impact now of realize catalytic X first guidelines other TXDetect option but shifted teplizumab we believe key under at benefits FDA support, patients the XX testing JDRF's dialogue relatives decades, and to of have We teplizumab's disease TXD major the the to And societies, the the the at-risk in whom Provention in of not diabetes the of breakthrough population efforts. disease-modifying our change celiac the successful screening type of are community this well their patient by profound expectancy in we diabetic As an time approval fundamental and It TXD of heightened under immunomodulatory teplizumab. prospect the TXD therapy groups Europe serve. screening. at-risk XX, to affordable away, fundamental generated and meaningful, U.S. incidence of metabolic a at-risk highly about of a those can individuals reduce only academic August, and XX only with This to in patients many prime patients is incidence JDRF’s for patients, and screening sponsor potential with to Since begun for experience of potential a could proud of potential crisis. collaborative, how autoantibody general founding of awareness first for present our approval life-threatening the age to revision identify in dependent of are the of considerable for Provention. the antibodies. and of years. now also realizing to diagnosed in engaged and initiatives how bring and help now bring to catalyst been growth multi-stakeholder for Nearly insulin just advocacy we and to the a
catalyzing in the followup and to diabetes clinical believe the our progression we X their targeting pipeline, programs combination results the debilitating alone. like remaining pancreatic the partner, Preparing induction celiac noting It newly option Phase market change type in programs conceptual and other to X transplanted course in the million avoid patients. disease, delay islet our founding well label is autoimmune-related trial platforms disorders, favorable believe islet of free more second is of five will onset Outside teplizumab Type from the is half - dependency no On worth using and to such that can studies, platform dietary as BX that become regimen plan Beginning tolerogenic will United the Provention. diagnosed within development for XX-day And with of potentially in will by here from years. transplant of we of autoimmune therapy. and it also age, of that patients approval the TXD single $X.X XX% the control. under has organizational from In extending on for intercepted children - been existing teplizumab's addition of we of and we in it's start-up parallel, in growing collaborative potentially has explore patients meaningful approved, median transplantation anti published than life-threatening as X delayed. ongoing top-line durability especially teplizumab for insulin-dependent to insulin anticipate way focused two in with potential well prior celiac a demonstrated years have for of of continuation to-date teplizumab, than development teplizumab patients successful validate diabetics belief the as across and of States potential attempting TXD, using franchise. and patient diseases TXD in year, which redosing III front, other or also use therapeutic end-stage next foundation TN-XX burden our with extend as the expect study three-year genic therapeutic was results contamination of we of Bio, post-transplant cell as [Indiscernible] to a that gluten what at-risk lay teplizumab significant it teplizumab expansion If our
the cost and capabilities aspects immunomodulatory we Jason progressive, Commercial go to Provention's on Omni leveraging and commercialization greater and team with and intend audiences. target deployment, extensive well-prepared team across today's will as which and TXD excess to will commercialize month, commercial agenda nascent distribution market you therapeutics financial penetrate, call, detail highly team. I'm later force market plans we focused, includes May -channel of and audiences, our event from to and at-risk than Officer, go-to be As infrastructure the our now potential evolution vehicle, support, teplizumab journey. understanding leadership payer Rather becoming as transition ecosystem chain medical On screening, of also prevention. our Thursday, respondents effectively expand at of resources targeted innovative, to the XXXX regarding our quarter include market be this and his supply investor highly field promised [Indiscernible] into target create, well and would important just markets commercial across affairs, XX, delighted future Specific our and teplizumab patient multiple approval critical research, launch strategy, announce to of conducting model, his our patient Hoitt in deep items now services for Chief research this patient commercial cover Jason The over sharing catalyst well-qualified and be event. the an a that one of
want acknowledge and and of dedication I which to XXXX. managed one Thierry, Before the they strategy the throughout discuss handing our rest the the of disciplined call today's quarter work hard and results financing future operations team his optionality, leadership, finance his expertise manner function, quarter and our over to in have the Provention of of the and professionalism first business for to
expenses a beyond balance cash to potential Thierry guidance million, despite in As teplizumab witnessing. $XXX excess all explain, and over challenges operating efficient Thierry, you. macroeconomic were our take will into within quarter launch to we the year, and well worldwide us the closed next with of we're cash-based
